Literature DB >> 17089202

Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.

Johannes H Proost1, Douglas J Eleveld.   

Abstract

PURPOSE: To test the suitability of an Iterative Two-Stage Bayesian (ITSB) technique for population pharmacokinetic analysis of rich data sets, and to compare ITSB with Standard Two-Stage (STS) analysis and nonlinear Mixed Effect Modeling (MEM).
MATERIALS AND METHODS: Data from a clinical study with rapacuronium and data generated by Monte Carlo simulation were analyzed by an ITSB technique described in literature, with some modifications, by STS, and by MEM (using NONMEM). The results were evaluated by comparing the mean error (accuracy) and root mean squared error (precision) of the estimated parameter values, their interindividual standard deviation, correlation coefficients, and residual standard deviation. In addition, the influence of initial estimates, number of subjects, number of measurements, and level of residual error on the performance of ITSB were investigated.
RESULTS: ITSB yielded best results, and provided precise and virtually unbiased estimates of the population parameter means, interindividual variability, and residual standard deviation. The accuracy and precision of STS was poor, whereas ITSB performed better than MEM.
CONCLUSIONS: ITSB is a suitable technique for population pharmacokinetic analysis of rich data sets, and in the presented data set it is superior to STS and MEM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089202     DOI: 10.1007/s11095-006-9116-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

2.  MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.

Authors:  J H Proost; D K Meijer
Journal:  Comput Biol Med       Date:  1992-05       Impact factor: 4.589

3.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

5.  A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.

Authors:  F Mentré; R Gomeni
Journal:  J Biopharm Stat       Date:  1995-07       Impact factor: 1.051

6.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.

Authors:  J L Steimer; A Mallet; J L Golmard; J F Boisvieux
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

7.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

8.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

Review 9.  Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.

Authors:  R W Jelliffe; A Schumitzky; D Bayard; M Milman; M Van Guilder; X Wang; F Jiang; X Barbaut; P Maire
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

10.  Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488).

Authors:  S Schiere; J H Proost; M Schuringa; J M Wierda
Journal:  Anesth Analg       Date:  1999-03       Impact factor: 5.108

View more
  25 in total

1.  Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients.

Authors:  Franck Saint-Marcoux; Soizic Vandierdonck; Aurélie Prémaud; Jean Debord; Annick Rousseau; Pierre Marquet
Journal:  Ther Drug Monit       Date:  2011-06       Impact factor: 3.681

2.  Renal function assessment in older adults.

Authors:  A Clara Drenth-van Maanen; Paul A F Jansen; Johannes H Proost; Toine C G Egberts; Arjan D van Zuilen; Dawi van der Stap; Rob J van Marum
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

3.  A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts.

Authors:  Frank Stifft; Franciscus Vandermeer; Cees Neef; Sander van Kuijk; Maarten H L Christiaans
Journal:  Eur J Clin Pharmacol       Date:  2020-02-04       Impact factor: 2.953

4.  A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity.

Authors:  H W Heetla; J H Proost; B H Molmans; M J Staal; T van Laar
Journal:  Br J Clin Pharmacol       Date:  2016-01       Impact factor: 4.335

5.  An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data.

Authors:  Jijie Li; Kewei Yan; Lisha Hou; Xudong Du; Ping Zhu; Li Zheng; Cairong Zhu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

6.  Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

Authors:  S P van Rijn; M A Zuur; R van Altena; O W Akkerman; J H Proost; W C M de Lange; H A M Kerstjens; D J Touw; T S van der Werf; J G W Kosterink; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

7.  Pharmacokinetic modeling of gentamicin in treatment of infective endocarditis: Model development and validation of existing models.

Authors:  Anna Gomes; Lars van der Wijk; Johannes H Proost; Bhanu Sinha; Daan J Touw
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

8.  Limited-sampling strategies for anidulafungin in critically ill patients.

Authors:  Marjolijn J P van Wanrooy; Johannes H Proost; Michael G G Rodgers; Jan G Zijlstra; Donald R A Uges; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

9.  Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.

Authors:  N Alsaad; J A Dijkstra; O W Akkerman; W C M de Lange; D van Soolingen; J G W Kosterink; T S van der Werf; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate.

Authors:  Jeanne Fourie Zirkelbach; Andre J Jackson; Yaning Wang; Donald J Schuirmann
Journal:  Pharm Res       Date:  2012-09-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.